沃华医药
(002107)
| 流通市值：28.65亿 | | | 总市值：29.03亿 |
| 流通股本：5.70亿 | | | 总股本：5.77亿 |
| 报告期 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 流动资产: | | | | |
| 货币资金 | 327,460,207.48 | 314,982,248.77 | 456,686,925.02 | 401,100,106.17 |
| 应收票据及应收账款 | 65,782,797.54 | 65,759,812.72 | 66,323,605.83 | 82,771,201.56 |
| 其中：应收票据 | 1,552,808.71 | 2,752,784.85 | 2,964,959.49 | 3,288,588.46 |
| 应收账款 | 64,229,988.83 | 63,007,027.87 | 63,358,646.34 | 79,482,613.1 |
| 应收款项融资 | 3,929,365.17 | 5,253,604.78 | 8,662,268.08 | 16,434,454.26 |
| 预付款项 | 2,205,487.95 | 3,597,615.12 | 3,319,842.68 | 2,206,886.28 |
| 其他应收款合计 | 15,669,601.19 | 15,374,604.64 | 15,841,587.08 | 14,341,595.95 |
| 存货 | 115,227,500.42 | 132,304,052.49 | 140,891,997.39 | 149,086,389.06 |
| 其他流动资产 | 6,578,522.76 | 6,892,182.7 | 6,565,438.39 | 7,061,524.48 |
| 流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 流动资产合计 | 536,853,482.51 | 544,164,121.22 | 698,291,664.47 | 673,002,157.76 |
| 非流动资产: | | | | |
| 投资性房地产 | 17,836,126.41 | 18,019,236.4 | 18,197,503.11 | 18,378,191.46 |
| 固定资产 | 360,667,316.95 | 367,768,841.22 | 375,025,141.9 | 382,553,741.42 |
| 使用权资产 | - | 70,450.4 | 246,067.58 | 421,684.76 |
| 无形资产 | 35,883,474.79 | 36,202,851.49 | 36,522,228.19 | 36,841,604.89 |
| 商誉 | 32,508,664.53 | 32,508,664.53 | 32,508,664.53 | 32,508,664.53 |
| 递延所得税资产 | 623,148.26 | 599,930.52 | 651,504.39 | 728,343.76 |
| 其他非流动资产 | 416,126 | 279,250 | 309,580 | 272,000 |
| 非流动资产平衡项目 | 0 | 0 | 0 | 0 |
| 非流动资产合计 | 447,934,856.94 | 455,449,224.56 | 463,460,689.7 | 471,704,230.82 |
| 资产平衡项目 | 0 | 0 | 0 | 0 |
| 资产总计 | 984,788,339.45 | 999,613,345.78 | 1,161,752,354.17 | 1,144,706,388.58 |
| 流动负债: | | | | |
| 应付票据及应付账款 | 49,575,749.15 | 57,175,051.96 | 58,144,991.48 | 54,469,268.99 |
| 其中：应付票据 | 6,861,600.2 | 7,357,600.2 | 496,000 | 1,543,755 |
| 应付账款 | 42,714,148.95 | 49,817,451.76 | 57,648,991.48 | 52,925,513.99 |
| 合同负债 | 4,161,199.46 | 6,051,857.79 | 7,057,681.57 | 5,596,928.81 |
| 应付职工薪酬 | 6,549,867.06 | 8,760,694.4 | 7,642,921.57 | 10,394,082.85 |
| 应交税费 | 10,558,827.87 | 8,609,809.79 | 11,034,238.6 | 13,390,741.96 |
| 其他应付款合计 | 35,216,470.38 | 36,808,816.92 | 38,933,340.19 | 38,518,812.39 |
| 一年内到期的非流动负债 | - | 87,426.49 | 213,131.06 | 400,613.73 |
| 其他流动负债 | 149,187,680.17 | 162,316,511.3 | 174,199,432.93 | 165,220,383.23 |
| 流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 流动负债合计 | 255,249,794.09 | 279,810,168.65 | 297,225,737.4 | 287,990,831.96 |
| 非流动负债: | | | | |
| 长期应付职工薪酬 | 233,407.87 | 276,673.02 | 323,748.37 | 426,867.63 |
| 预计负债 | - | - | 219,057.22 | 297,776.86 |
| 递延收益 | 15,698,511.34 | 16,431,526.51 | 17,164,541.68 | 17,926,306.85 |
| 递延所得税负债 | 4,291,798.3 | 4,300,583.13 | 4,577,786.9 | 4,586,571.73 |
| 非流动负债平衡项目 | 0 | 0 | 0 | 0 |
| 非流动负债合计 | 20,223,717.51 | 21,008,782.66 | 22,285,134.17 | 23,237,523.07 |
| 负债平衡项目 | 0 | 0 | 0 | 0 |
| 负债合计 | 275,473,511.6 | 300,818,951.31 | 319,510,871.57 | 311,228,355.03 |
| 所有者权益(或股东权益): | | | | |
| 实收资本(或股本) | 577,209,600 | 577,209,600 | 577,209,600 | 577,209,600 |
| 盈余公积 | 44,242,510.95 | 44,242,510.95 | 44,242,510.95 | 44,242,510.95 |
| 未分配利润 | 62,422,443.4 | 50,594,309.94 | 193,482,438.34 | 183,815,215.11 |
| 归属于母公司股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 归属于母公司股东权益合计 | 683,874,554.35 | 672,046,420.89 | 814,934,549.29 | 805,267,326.06 |
| 少数股东权益 | 25,440,273.5 | 26,747,973.58 | 27,306,933.31 | 28,210,707.49 |
| 股东权益平衡项目 | 0 | 0 | 0 | 0 |
| 股东权益合计 | 709,314,827.85 | 698,794,394.47 | 842,241,482.6 | 833,478,033.55 |
| 负债和股东权益合计 | 984,788,339.45 | 999,613,345.78 | 1,161,752,354.17 | 1,144,706,388.58 |
| 公告日期 | 2024-10-26 | 2024-08-03 | 2024-04-27 | 2024-03-30 |
| 审计意见(境内) | | | | 标准无保留意见 |